FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Sept. 18, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to...